Yale Cancer Center study validates combination therapy for aggressive endometrial cancer

(Yale University) Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news